<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00049517</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000258113</org_study_id>
    <secondary_id>U10CA021115</secondary_id>
    <secondary_id>E1900</secondary_id>
    <nct_id>NCT00049517</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With AML Leukemia</brief_title>
  <official_title>A Phase III Trial in Adult Acute Myeloid Leukemia: Daunorubicin Dose-Intensification Prior to Risk-Allocated Autologous Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eastern Cooperative Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Eastern Cooperative Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Giving combination chemotherapy before a stem cell transplant helps stop the
      growth of cancer cells. It also helps stop the patient's immune system from rejecting the
      transplanted stem cells. When the healthy stem cells are infused into the patient they may
      help the patient's bone marrow make stem cells, red blood cells, white blood cells, and
      platelets. If the patient's stem cells are to be transplanted, the patient is also treated
      with a monoclonal antibody, such as gemtuzumab ozogamicin, to kill any remaining cancer cells
      or deliver cancer-killing substances to them without harming normal cells. It is not yet
      known whether combination chemotherapy is more effective with or without gemtuzumab
      ozogamicin followed by stem cell transplant in treating acute myeloid leukemia.

      PURPOSE: This randomized phase III trial is studying combination chemotherapy, gemtuzumab
      ozogamicin, and stem cell transplant to see how well they work compared to combination
      chemotherapy and peripheral stem cell transplant alone in treating patients with acute
      myeloid leukemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  To compare the overall survival (OS) between two induction regimens (standard versus
           dose intense daunorubicin and cytarabine) in patients with de novo AML.

        -  To compare disease-free survival (DFS) between two consolidation regimens.

        -  To compare overall survival between two consolidation regimens.

      OUTLINE: This is a randomized, multicenter study. Patients are stratified according to
      induction therapy (standard-dose daunorubicin vs high-dose daunorubicin).

        -  Induction therapy: Patients are randomized to 1 of 2 induction arms.

             -  Standard: Patients receive standard-dose daunorubicin IV over 10-15 minutes on days
                1-3 and cytarabine IV continuously on days 1-7.

             -  High dose: Patients receive high-dose daunorubicin IV over 10-15 minutes on days
                1-3 and cytarabine as in arm I.

      Patients in both arms may receive a second course of induction therapy if complete remission
      (CR) is not achieved after the first course. The second course is administered as in arm I to
      all patients. Patients who don't achieve CR after 2 courses of induction therapy are removed
      from study.

      Patients who achieve CR after induction therapy proceed to post-remission therapy with EITHER
      allogeneic transplantation only (on or off study) OR consolidation therapy and autologous
      transplantation (on study), according to risk status and donor status.

      Patients who are considered at intermediate or high risk for relapse (unfavorable
      cytogenetics/high WBC) and have a suitable related donor undergo an allogeneic
      transplantation. Patients with intermediate-risk cytogenetics, WBC no greater than
      100,000/mm^3, and appropriate donors have the option of undergoing allogeneic
      transplantation.

        -  Allogeneic transplantation: Within 1-3 months after recovery from induction therapy,
           patients receive busulfan IV every 6 hours on days -7 to -4 and cyclophosphamide IV over
           4 hours on days -3 and -2. Allogeneic bone marrow or peripheral blood stem cells (PBSCs)
           are infused on day 0. Patients receive graft-vs-host disease (GVHD) prophylaxis
           comprising cyclosporine IV over 1-4 hours beginning on day -1 and then orally (when
           tolerated) twice daily until day 180. Alternatively, patients may receive tacrolimus IV
           over 24 hours beginning on day -1 and then orally twice daily until day 180. Patients
           also receive methotrexate IV on days 1, 3, 6, and 11.

      Patients who do not meet the criteria for allogeneic transplantation (i.e., are favorable
      risk or do not have a matching related donor) or who opt not to undergo allogeneic
      transplantation proceed to consolidation therapy followed by randomization to 1 of 2
      autologous transplantation arms.

        -  Consolidation therapy: Beginning 2-8 weeks after recovery from induction therapy,
           patients receive high-dose cytarabine IV over 3 hours every 12 hours on days 1, 3, and
           5. A second course is administered 3 weeks after blood recovery. Patients receive
           filgrastim (G-CSF) subcutaneously (SC) daily for 4 days and then autologous PBSCs are
           harvested by leukapheresis.

        -  Autologous stem cell transplantation: Patients are randomized to 1 of 2 autologous
           transplantation arms.

             -  Arm I: Within 1 month after PBSC collection, patients receive conditioning
                comprising busulfan IV every 6 hours on days -7 to -4 and cyclophosphamide IV over
                2 hours on days -3 and -2. Patients then undergo autologous PBSC transplantation on
                day 0. Patients receive sargramostim (GM-CSF) or G-CSF IV or SC beginning on day 0
                and continuing until blood counts recover.

             -  Arm II (closed to accrual as of 10/4/2007): Within 2-4 weeks after PBSC collection,
                patients receive gemtuzumab ozogamicin IV over 2 hours on day 1 and GM-CSF SC or IV
                beginning on day 10 and continuing until blood counts recover. Within 2-3 weeks
                after blood count recovery, patients receive conditioning and undergo autologous
                PBSC transplantation as in arm I.

      Patients are followed monthly for 1 year, every 2 months for 1 year, and then every 3 months
      for up to 7 years.

      ACTUAL ACCRUAL: A total of 657 patients were accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>December 2002</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival (Induction Phase)</measure>
    <time_frame>Assessed during the first 4 months, then at least every three months for 2 years. then every six months until 5 years after study entry and every 12 months thereafter.</time_frame>
    <description>Overall survival is defined as the time from randomization in the induction phase to death.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease-free Survival (Consolidation Phase)</measure>
    <time_frame>Assessed during the first 4 months, then at least every three months for 2 years. then every six months until five years after study entry, and every 12 months thereafter.</time_frame>
    <description>Disease-free survival is defined from the time of the confirmation of a complete remission via biopsy to the relapse of the disease.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (Consolidation Phase)</measure>
    <time_frame>Assessed during the first 4 months, then at least every three months for 2 years. then every six months until five years after study entry, and every 12 months thereafter.</time_frame>
    <description>Overall survival is defined as the time from randomization in the consolidation phase to death.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">657</enrollment>
  <condition>Leukemia</condition>
  <arm_group>
    <arm_group_label>Standard Daunorubicin Then Autologous HCT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction: Patients receive standard-dose daunorubicin IV over 10-15 minutes on days 1-3 and cytarabine IV continuously on days 1-7. Patients may receive a second course of induction therapy if complete remission (CR) is not achieved after the first course.
Consolidation/Transplant:
Before initiating consolidation therapy, patients with CR were randomized to a standard or an investigational arm. All patients received 2 cycles of high-dose cytarabine therapy (3 g/m2 given IV over a 3-hour period every 12 hours every other day for a total of 6 doses), followed by sargramostim 250 μg/m2 until recovery of blood counts.
The patients undergoing autologous hematopoietic cell transplantation (HCT) received intravenous busulfan 0.8 mg/kg every 6 hours for 16 doses (without pharmacokinetic sampling) followed by intravenous cyclophosphamide 60 mg/kg daily for 2 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High-dose Daunorubicin Then Autologous HCT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction: Patients receive high-dose daunorubicin IV over 10-15 minutes on days 1-3 and cytarabine IV continuously on days 1-7. Patients may receive a second course of induction therapy if complete remission (CR) is not achieved after the first course.
Consolidation/Transplant:
Before initiating consolidation therapy, patients with CR were randomized to a standard or an investigational arm. All patients received 2 cycles of high-dose cytarabine therapy (3 g/m2 given IV over a 3-hour period every 12 hours every other day for a total of 6 doses), followed by sargramostim 250 μg/m2 until recovery of blood counts.
The patients undergoing autologous hematopoietic cell transplantation (HCT) received intravenous busulfan 0.8 mg/kg every 6 hours for 16 doses (without pharmacokinetic sampling) followed by intravenous cyclophosphamide 60 mg/kg daily for 2 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Daunorubicin Then GO/Autologous HCT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction: Patients receive standard-dose daunorubicin IV over 10-15 minutes on days 1-3 and cytarabine IV continuously on days 1-7. Patients may receive a second course of induction therapy if complete remission (CR) is not achieved after the first course.
Consolidation/Transplant:
Before initiating consolidation therapy, patients with CR were randomized to a standard or an investigational arm. All patients received 2 cycles of high-dose cytarabine therapy (3 g/m2 given IV over a 3-hour period every 12 hours every other day for a total of 6 doses), followed by sargramostim 250 μg/m2 until recovery of blood counts. patients randomized to the investigational arm received a single dose of Gemtuzumab ozogamicin (GO) at 6 mg/m2 followed by sargramostim 250 μ/m2 until recovery of counts.
The patients undergoing autologous HCT received intravenous busulfan 0.8 mg/kg every 6 hours for 16 doses followed by intravenous cyclophosphamide 60 mg/kg daily for 2 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High-dose Daunorubicin Then GO/Autologous HCT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction: Patients receive high-dose daunorubicin IV over 10-15 minutes on days 1-3 and cytarabine IV continuously on days 1-7. Patients may receive a second course of induction therapy if complete remission (CR) is not achieved after the first course.
Consolidation/Transplant:
Before initiating consolidation therapy, patients with CR were randomized to a standard or an investigational arm. All patients received 2 cycles of high-dose cytarabine therapy (3 g/m2 given IV over a 3-hour period every 12 hours every other day for a total of 6 doses), followed by sargramostim 250 μg/m2 until recovery of blood counts. patients randomized to the investigational arm received a single dose of Gemtuzumab ozogamicin (GO) at 6 mg/m2 followed by sargramostim 250 μ/m2 until recovery of counts.
The patients undergoing autologous HCT received intravenous busulfan 0.8 mg/kg every 6 hours for 16 doses followed by intravenous cyclophosphamide 60 mg/kg daily for 2 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Daunorubicin Then Allogeneic HCT or no Consolidation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Induction: Patients receive standard-dose daunorubicin IV over 10-15 minutes on days 1-3 and cytarabine IV continuously on days 1-7. Patients may receive a second course of induction therapy if complete remission (CR) is not achieved after the first course.
Consolidation/Transplant:
Patients without CR did not receive any consolidation treatment. Patients in CR with an unfavorable cytogenetic profile or an initial white blood cell count &gt; 100,000/μL were to proceed to allogeneic HCT if they had a suitable human leukocyte antigen (HLA)-matched sibling donor available.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High-dose Daunorubicin Then Allogeneic HCT or no Consolidation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction: Patients receive high-dose daunorubicin IV over 10-15 minutes on days 1-3 and cytarabine IV continuously on days 1-7. Patients may receive a second course of induction therapy if complete remission (CR) is not achieved after the first course.
Consolidation/Transplant:
Patients without CR did not receive any consolidation treatment. Patients in CR with an unfavorable cytogenetic profile or an initial white blood cell count &gt; 100,000/μL were to proceed to allogeneic HCT if they had a suitable human leukocyte antigen (HLA)-matched sibling donor available.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>sargramostim</intervention_name>
    <description>Given IV or as an injection</description>
    <arm_group_label>Standard Daunorubicin Then Autologous HCT</arm_group_label>
    <arm_group_label>High-dose Daunorubicin Then Autologous HCT</arm_group_label>
    <arm_group_label>Standard Daunorubicin Then GO/Autologous HCT</arm_group_label>
    <arm_group_label>High-dose Daunorubicin Then GO/Autologous HCT</arm_group_label>
    <other_name>Leukine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>busulfan</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Standard Daunorubicin Then Autologous HCT</arm_group_label>
    <arm_group_label>High-dose Daunorubicin Then Autologous HCT</arm_group_label>
    <arm_group_label>Standard Daunorubicin Then GO/Autologous HCT</arm_group_label>
    <arm_group_label>High-dose Daunorubicin Then GO/Autologous HCT</arm_group_label>
    <other_name>Myleran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Standard Daunorubicin Then Autologous HCT</arm_group_label>
    <arm_group_label>High-dose Daunorubicin Then Autologous HCT</arm_group_label>
    <arm_group_label>Standard Daunorubicin Then GO/Autologous HCT</arm_group_label>
    <arm_group_label>High-dose Daunorubicin Then GO/Autologous HCT</arm_group_label>
    <other_name>Endoxan</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Neosar</other_name>
    <other_name>Procytox</other_name>
    <other_name>Revimmune</other_name>
    <other_name>cytophosphane</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytarabine</intervention_name>
    <description>Given as a continuous infusion</description>
    <arm_group_label>Standard Daunorubicin Then Autologous HCT</arm_group_label>
    <arm_group_label>High-dose Daunorubicin Then Autologous HCT</arm_group_label>
    <arm_group_label>Standard Daunorubicin Then GO/Autologous HCT</arm_group_label>
    <arm_group_label>High-dose Daunorubicin Then GO/Autologous HCT</arm_group_label>
    <arm_group_label>Standard Daunorubicin Then Allogeneic HCT or no Consolidation</arm_group_label>
    <arm_group_label>High-dose Daunorubicin Then Allogeneic HCT or no Consolidation</arm_group_label>
    <other_name>cytosine arabinoside</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemtuzumab ozogamicin (GO)</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Standard Daunorubicin Then GO/Autologous HCT</arm_group_label>
    <arm_group_label>High-dose Daunorubicin Then GO/Autologous HCT</arm_group_label>
    <other_name>Mylotarg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daunorubicin</intervention_name>
    <description>Given intravenously daily for 3 days at a dose of either 45 or 90 mg/m2.</description>
    <arm_group_label>Standard Daunorubicin Then Autologous HCT</arm_group_label>
    <arm_group_label>High-dose Daunorubicin Then Autologous HCT</arm_group_label>
    <arm_group_label>Standard Daunorubicin Then GO/Autologous HCT</arm_group_label>
    <arm_group_label>High-dose Daunorubicin Then GO/Autologous HCT</arm_group_label>
    <arm_group_label>Standard Daunorubicin Then Allogeneic HCT or no Consolidation</arm_group_label>
    <arm_group_label>High-dose Daunorubicin Then Allogeneic HCT or no Consolidation</arm_group_label>
    <other_name>daunomycin</other_name>
    <other_name>daunomycin cerubidine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Autologous HCT</intervention_name>
    <description>Autologous hematopoietic cell transplantation</description>
    <arm_group_label>Standard Daunorubicin Then Autologous HCT</arm_group_label>
    <arm_group_label>High-dose Daunorubicin Then Autologous HCT</arm_group_label>
    <arm_group_label>Standard Daunorubicin Then GO/Autologous HCT</arm_group_label>
    <arm_group_label>High-dose Daunorubicin Then GO/Autologous HCT</arm_group_label>
    <other_name>Autologous hematopoietic cell transplantation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Allogeneic HCT</intervention_name>
    <description>Allogeneic hematopoietic cell transplantation</description>
    <arm_group_label>Standard Daunorubicin Then Allogeneic HCT or no Consolidation</arm_group_label>
    <arm_group_label>High-dose Daunorubicin Then Allogeneic HCT or no Consolidation</arm_group_label>
    <other_name>Allogeneic hematopoietic cell transplantation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Morphologically confirmed acute myeloid leukemia (AML) (greater than 20% blasts in the
             peripheral blood or marrow) meeting any of the following criteria:

               -  Recurrent cytogenetic translocations

                    -  t(8;21)(q22;q22)

                    -  Bone marrow eosinophil abnormalities

                         -  inv(16)(p13;q22)

                         -  t(16;16)(p13;q22)

                    -  11q23 abnormalities

               -  Multilineage dysplasia without presence of myelodysplastic syndromes (MDS)

               -  Minimally differentiated AML

               -  AML without maturation

               -  AML with maturation

               -  AML not otherwise categorized

               -  Acute myelomonocytic leukemia

               -  Acute monocytic leukemia

               -  Acute erythroid leukemia

               -  Acute megakaryocytic leukemia

               -  Acute basophilic leukemia

          -  Patients undergoing allogeneic transplantation must have a sibling donor match defined
             as human leukocyte antigen (HLA) match or haplotype match with one locus mismatch on
             other haplotype

          -  Age 16 to 60

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-4

          -  Aspartate aminotransferase (AST) less than 4 times upper limit of normal (ULN)

          -  Alkaline phosphatase less than 4 times ULN

          -  Creatinine no greater than 2.0 mg/dL

          -  Creatinine clearance at least 50 mL/min

          -  Left ventricular ejection fraction (LVEF) at least 45% by post-induction multigated
             acquisition (MUGA) scan

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  HIV negative

          -  Prior hydroxyurea allowed

          -  Prior corticosteroids allowed

        Exclusion Criteria:

          -  Recurrent cytogenetic translocations

               -  Acute promyelocytic leukemia (PML) with t(15;17)(q22;q21)

               -  Variant acute PML with t(v;17)

          -  Multilineage dysplasia with prior MDS

          -  Acute panmyelosis with myelofibrosis

               -  Blastic transformation of chronic myelogenous leukemia

               -  Secondary AML (chemotherapy-induced or evolved from MDS)

               -  Pregnant or nursing

               -  Bilirubin greater than 2.0 mg/dL (unless related to Gilbert's syndrome or
                  hemolysis)

               -  Significant cardiac disease requiring active therapy (e.g., digoxin, diuretics,
                  antiarrhythmics, or antianginal medications)

               -  Prior biologic therapy

               -  Prior cytotoxic chemotherapy for any malignancy

               -  Prior radiotherapy for any malignancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hugo F. Fernandez, MD</last_name>
    <role>Study Chair</role>
    <affiliation>H. Lee Moffitt Cancer Center and Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lurleen Wallace Comprehensive Cancer at University of Alabama - Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Scottsdale</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259-5499</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aurora Presbyterian Hospital</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penrose Cancer Center at Penrose Hospital</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80933</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Anthony Central Hospital</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Porter Adventist Hospital</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Presbyterian - St. Luke's Medical Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph Hospital</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rose Medical Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Colorado Cancer Research Program</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80224-2522</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <zip>80110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Mary's Regional Cancer Center at St. Mary's Hospital and Medical Center</name>
      <address>
        <city>Grand Junction</city>
        <state>Colorado</state>
        <zip>81502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Colorado Medical Center</name>
      <address>
        <city>Greeley</city>
        <state>Colorado</state>
        <zip>80631</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sky Ridge Medical Center</name>
      <address>
        <city>Lone Tree</city>
        <state>Colorado</state>
        <zip>80124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hope Cancer Care Center at Longmont United Hospital</name>
      <address>
        <city>Longmont</city>
        <state>Colorado</state>
        <zip>80502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McKee Medical Center</name>
      <address>
        <city>Loveland</city>
        <state>Colorado</state>
        <zip>80539</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Mary - Corwin Regional Medical Center</name>
      <address>
        <city>Pueblo</city>
        <state>Colorado</state>
        <zip>81004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Suburban Medical Center</name>
      <address>
        <city>Thornton</city>
        <state>Colorado</state>
        <zip>80229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Exempla Lutheran Medical Center</name>
      <address>
        <city>Wheat Ridge</city>
        <state>Colorado</state>
        <zip>80033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eugene M. and Christine E. Lynn Cancer Institute at Boca Raton Community Hospital - West</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33428</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eugene M. and Christine E. Lynn Cancer Institute at Boca Raton Community Hospital - Main Campus</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33486</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida Shands Cancer Center</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610-0232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami Sylvester Comprehensive Cancer Center - Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute of Emory University</name>
      <address>
        <city>Altanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robert H. Lurie Comprehensive Cancer Center at Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611-3013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology and Oncology Associates</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evanston Northwestern Healthcare - Evanston Hospital</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201-1781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Center for Hematology/Oncology</name>
      <address>
        <city>Joliet</city>
        <state>Illinois</state>
        <zip>60432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Joliet Oncology-Hematology Associates, Limited - West</name>
      <address>
        <city>Joliet</city>
        <state>Illinois</state>
        <zip>60435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Shore Oncology and Hematology Associates, Limited - Libertyville</name>
      <address>
        <city>Libertyville</city>
        <state>Illinois</state>
        <zip>60048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>La Grange Oncology Associates - Geneva</name>
      <address>
        <city>Naperville</city>
        <state>Illinois</state>
        <zip>60563</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Care and Hematology Specialists of Chicagoland - Niles</name>
      <address>
        <city>Niles</city>
        <state>Illinois</state>
        <zip>60714</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advocate Lutheran General Cancer Care Center</name>
      <address>
        <city>Park Ridge</city>
        <state>Illinois</state>
        <zip>60068-1174</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology Oncology Associates - Skokie</name>
      <address>
        <city>Skokie</city>
        <state>Illinois</state>
        <zip>60076</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carle Cancer Center at Carle Foundation Hospital</name>
      <address>
        <city>Urbana</city>
        <state>Illinois</state>
        <zip>61801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Carle Cancer Center</name>
      <address>
        <city>Urbana</city>
        <state>Illinois</state>
        <zip>61801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fort Wayne Medical Oncology and Hematology</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46815</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Melvin and Bren Simon Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202-5289</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tufts-NEMC Cancer Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Borgess Medical Center</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Michigan Cancer Center</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49007-3731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bronson Methodist Hospital</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MeritCare Bemidji</name>
      <address>
        <city>Bemidji</city>
        <state>Minnesota</state>
        <zip>56601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fairview Ridges Hospital</name>
      <address>
        <city>Burnsville</city>
        <state>Minnesota</state>
        <zip>55337</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy and Unity Cancer Center at Mercy Hospital</name>
      <address>
        <city>Coon Rapids</city>
        <state>Minnesota</state>
        <zip>55433</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fairview Southdale Hospital</name>
      <address>
        <city>Edina</city>
        <state>Minnesota</state>
        <zip>55435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy and Unity Cancer Center at Unity Hospital</name>
      <address>
        <city>Fridley</city>
        <state>Minnesota</state>
        <zip>55432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minnesota Oncology Hematology, PA - Maplewood</name>
      <address>
        <city>Maplewood</city>
        <state>Minnesota</state>
        <zip>55109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Piper Cancer Institute at Abbott - Northwestern Hospital</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hubert H. Humphrey Cancer Center at North Memorial Outpatient Center</name>
      <address>
        <city>Robbinsdale</city>
        <state>Minnesota</state>
        <zip>55422-2900</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Cancer Center</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Metro-Minnesota</name>
      <address>
        <city>Saint Louis Park</city>
        <state>Minnesota</state>
        <zip>55416</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Park Nicollet Cancer Center</name>
      <address>
        <city>Saint Louis Park</city>
        <state>Minnesota</state>
        <zip>55416</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>United Hospital</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ridgeview Medical Center</name>
      <address>
        <city>Waconia</city>
        <state>Minnesota</state>
        <zip>55387</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minnesota Oncology Hematology, PA - Woodbury</name>
      <address>
        <city>Woodbury</city>
        <state>Minnesota</state>
        <zip>55125</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Montana Cancer Consortium</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology-Oncology Centers of the Northern Rockies - Billings</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern Rockies Radiation Oncology Center</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent Healthcare Cancer Care Services</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Billings Clinic - Downtown</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59107-7000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bozeman Deaconess Cancer Center</name>
      <address>
        <city>Bozeman</city>
        <state>Montana</state>
        <zip>59715</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. James Healthcare Cancer Care</name>
      <address>
        <city>Butte</city>
        <state>Montana</state>
        <zip>59701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Great Falls Clinic - Main Facility</name>
      <address>
        <city>Great Falls</city>
        <state>Montana</state>
        <zip>59405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Great Falls Clinic</name>
      <address>
        <city>Great Falls</city>
        <state>Montana</state>
        <zip>59405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Peter's Hospital</name>
      <address>
        <city>Helena</city>
        <state>Montana</state>
        <zip>59601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glacier Oncology, PLLC</name>
      <address>
        <city>Kalispell</city>
        <state>Montana</state>
        <zip>59901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kalispell Medical Oncology at KRMC</name>
      <address>
        <city>Kalispell</city>
        <state>Montana</state>
        <zip>59901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kalispell Regional Medical Center</name>
      <address>
        <city>Kalispell</city>
        <state>Montana</state>
        <zip>59901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Medical Center</name>
      <address>
        <city>Missoula</city>
        <state>Montana</state>
        <zip>59801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guardian Oncology and Center for Wellness</name>
      <address>
        <city>Missoula</city>
        <state>Montana</state>
        <zip>59804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montana Cancer Specialists at Montana Cancer Center</name>
      <address>
        <city>Missoula</city>
        <state>Montana</state>
        <zip>59807-7877</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montana Cancer Center at St. Patrick Hospital and Health Sciences Center</name>
      <address>
        <city>Missoula</city>
        <state>Montana</state>
        <zip>59807</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albert Einstein Cancer Center at Albert Einstein College of Medicine</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU Cancer Institute at New York University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - MeritCare Hospital</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MeritCare Broadway</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Cancer Center at Mercy Medical Center</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aultman Cancer Center at Aultman Hospital</name>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <zip>44710-1799</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jewish Hospital Cancer Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Rita's Medical Center</name>
      <address>
        <city>Lima</city>
        <state>Ohio</state>
        <zip>45801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Geisinger Cancer Institute at Geisinger Health</name>
      <address>
        <city>Danville</city>
        <state>Pennsylvania</state>
        <zip>17822-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn State Cancer Institute at Milton S. Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033-0850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abramson Cancer Center of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-4283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center - Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111-2497</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC Cancer Centers</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Geisinger Medical Group - Scenery Park</name>
      <address>
        <city>State College</city>
        <state>Pennsylvania</state>
        <zip>16801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frank M. and Dorothea Henry Cancer Center at Geisinger Wyoming Valley Medical Center</name>
      <address>
        <city>Wilkes-Barre</city>
        <state>Pennsylvania</state>
        <zip>18711</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-6838</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University Massey Cancer Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298-0037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marshfield Clinic Cancer Care at Regional Cancer Center</name>
      <address>
        <city>Eau Claire</city>
        <state>Wisconsin</state>
        <zip>54701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gundersen Lutheran Cancer Center at Gundersen Lutheran Medical Center</name>
      <address>
        <city>La Crosse</city>
        <state>Wisconsin</state>
        <zip>54601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Paul P. Carbone Comprehensive Cancer Center</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792-6164</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marshfield Clinic - Marshfield Center</name>
      <address>
        <city>Marshfield</city>
        <state>Wisconsin</state>
        <zip>54449</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Joseph's Hospital</name>
      <address>
        <city>Marshfield</city>
        <state>Wisconsin</state>
        <zip>54449</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ministry Medical Group at Saint Mary's Hospital</name>
      <address>
        <city>Rhinelander</city>
        <state>Wisconsin</state>
        <zip>54501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marshfield Clinic - Weston Center</name>
      <address>
        <city>Weston</city>
        <state>Wisconsin</state>
        <zip>54476</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Welch Cancer Center at Sheridan Memorial Hospital</name>
      <address>
        <city>Sheridan</city>
        <state>Wyoming</state>
        <zip>82801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Center</name>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Fernandez HF, Sun Z, Yao X, Litzow MR, Luger SM, Paietta EM, Racevskis J, Dewald GW, Ketterling RP, Bennett JM, Rowe JM, Lazarus HM, Tallman MS. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med. 2009 Sep 24;361(13):1249-59. doi: 10.1056/NEJMoa0904544.</citation>
    <PMID>19776406</PMID>
  </results_reference>
  <results_reference>
    <citation>Fernandez HF, Sun Z, Bennett JM, et al.: A single dose of gemtuzumab-ozogamicin (GO) in consolidation prior to autologous transplant for younger patients with newly diagnosed acute myeloid (AML) is safe but has no effect on disease free survival: interim results of Eastern Cooperative Oncology Group study (E1900). [Abstract] Biol Blood Marrow Transplant 14 (2): A-52, 21-2, 2008.</citation>
  </results_reference>
  <results_reference>
    <citation>Vance GH, Kim H, Hicks GA, Cherry AM, Higgins R, Hulshizer RL, Tallman MS, Fernandez HF, Dewald GW. Utility of interphase FISH to stratify patients into cytogenetic risk categories at diagnosis of AML in an Eastern Cooperative Oncology Group (ECOG) clinical trial (E1900). Leuk Res. 2007 May;31(5):605-9. Epub 2006 Sep 22.</citation>
    <PMID>16996130</PMID>
  </results_reference>
  <results_reference>
    <citation>Fernandez HF, Kim HT, Bennett JM, et al.: Gemtuzumab-ozogamicin (GO; mylotarg®) as part of consolidation therapy for AML before autograft: low incidence of hepatic veno-occlusive disease. [Abstract] Biol Blood Marrow Transplant 11 (2 Suppl 1): A-187, 2005.</citation>
  </results_reference>
  <results_reference>
    <citation>Gönen M, Sun Z, Figueroa ME, Patel JP, Abdel-Wahab O, Racevskis J, Ketterling RP, Fernandez H, Rowe JM, Tallman MS, Melnick A, Levine RL, Paietta E. CD25 expression status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase 3 trial, E1900. Blood. 2012 Sep 13;120(11):2297-306. doi: 10.1182/blood-2012-02-414425. Epub 2012 Aug 1.</citation>
    <PMID>22855599</PMID>
  </results_reference>
  <results_reference>
    <citation>Fernandez HF, Sun Z, Litzow MR, Luger SM, Paietta EM, Racevskis J, Dewald G, Ketterling RP, Rowe JM, Lazarus HM, Tallman MS. Autologous transplantation gives encouraging results for young adults with favorable-risk acute myeloid leukemia, but is not improved with gemtuzumab ozogamicin. Blood. 2011 May 19;117(20):5306-13. doi: 10.1182/blood-2010-09-309229. Epub 2011 Mar 17.</citation>
    <PMID>21415269</PMID>
  </results_reference>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 12, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <results_first_submitted>January 10, 2013</results_first_submitted>
  <results_first_submitted_qc>January 10, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 12, 2013</results_first_posted>
  <last_update_submitted>December 1, 2016</last_update_submitted>
  <last_update_submitted_qc>December 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>acute myeloid leukemia</keyword>
  <keyword>autologous transplantation</keyword>
  <keyword>gemtuzumab ozogamicin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Gemtuzumab</mesh_term>
    <mesh_term>Daunorubicin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>From December 2002 through November 2008, a total of 657 patients were enrolled in the study.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Standard Daunorubicin Then Autologous HCT</title>
          <description>Induction: Patients receive standard-dose daunorubicin IV over 10-15 minutes on days 1-3 and cytarabine IV continuously on days 1-7. Patients may receive a second course of induction therapy if complete remission (CR) is not achieved after the first course.
Consolidation/Transplant:
Before initiating consolidation therapy, patients with CR were randomized to a standard or an investigational arm. All patients received 2 cycles of high-dose cytarabine therapy (3 g/m2 given IV over a 3-hour period every 12 hours every other day for a total of 6 doses), followed by sargramostim 250 μg/m2 until recovery of blood counts.
The patients undergoing autologous hematopoietic cell transplantation (HCT) received intravenous busulfan 0.8 mg/kg every 6 hours for 16 doses (without pharmacokinetic sampling) followed by intravenous cyclophosphamide 60 mg/kg daily for 2 days.</description>
        </group>
        <group group_id="P2">
          <title>High-dose Daunorubicin Then Autologous HCT</title>
          <description>Induction: Patients receive high-dose daunorubicin IV over 10-15 minutes on days 1-3 and cytarabine IV continuously on days 1-7. Patients may receive a second course of induction therapy if complete remission (CR) is not achieved after the first course.
Consolidation/Transplant:
Before initiating consolidation therapy, patients with CR were randomized to a standard or an investigational arm. All patients received 2 cycles of high-dose cytarabine therapy (3 g/m2 given IV over a 3-hour period every 12 hours every other day for a total of 6 doses), followed by sargramostim 250 μg/m2 until recovery of blood counts.
The patients undergoing autologous hematopoietic cell transplantation (HCT) received intravenous busulfan 0.8 mg/kg every 6 hours for 16 doses (without pharmacokinetic sampling) followed by intravenous cyclophosphamide 60 mg/kg daily for 2 days.</description>
        </group>
        <group group_id="P3">
          <title>Standard Daunorubicin Then GO/Autologous HCT</title>
          <description>Induction: Patients receive standard-dose daunorubicin IV over 10-15 minutes on days 1-3 and cytarabine IV continuously on days 1-7. Patients may receive a second course of induction therapy if complete remission (CR) is not achieved after the first course.
Consolidation/Transplant:
Before initiating consolidation therapy, patients with CR were randomized to a standard or an investigational arm. All patients received 2 cycles of high-dose cytarabine therapy (3 g/m2 given IV over a 3-hour period every 12 hours every other day for a total of 6 doses), followed by sargramostim 250 μg/m2 until recovery of blood counts. patients randomized to the investigational arm received a single dose of Gemtuzumab ozogamicin (GO) at 6 mg/m2 followed by sargramostim 250 μ/m2 until recovery of counts.
The patients undergoing autologous HCT received intravenous busulfan 0.8 mg/kg every 6 hours for 16 doses followed by intravenous cyclophosphamide 60 mg/kg daily for 2 days.</description>
        </group>
        <group group_id="P4">
          <title>High-dose Daunorubicin Then GO/Autologous HCT</title>
          <description>Induction: Patients receive high-dose daunorubicin IV over 10-15 minutes on days 1-3 and cytarabine IV continuously on days 1-7. Patients may receive a second course of induction therapy if complete remission (CR) is not achieved after the first course.
Consolidation/Transplant:
Before initiating consolidation therapy, patients with CR were randomized to a standard or an investigational arm. All patients received 2 cycles of high-dose cytarabine therapy (3 g/m2 given IV over a 3-hour period every 12 hours every other day for a total of 6 doses), followed by sargramostim 250 μg/m2 until recovery of blood counts. patients randomized to the investigational arm received a single dose of Gemtuzumab ozogamicin (GO) at 6 mg/m2 followed by sargramostim 250 μ/m2 until recovery of counts.
The patients undergoing autologous HCT received intravenous busulfan 0.8 mg/kg every 6 hours for 16 doses followed by intravenous cyclophosphamide 60 mg/kg daily for 2 days.</description>
        </group>
        <group group_id="P5">
          <title>Standard Daunorubicin Then Allogeneic HCT or no Consolidation</title>
          <description>Induction: Patients receive standard-dose daunorubicin IV over 10-15 minutes on days 1-3 and cytarabine IV continuously on days 1-7. Patients may receive a second course of induction therapy if complete remission (CR) is not achieved after the first course.
Consolidation/Transplant:
Patients without CR did not receive any consolidation treatment. Patients in CR with an unfavorable cytogenetic profile or an initial white blood cell count &gt; 100,000/μL were to proceed to allogeneic HCT if they had a suitable human leukocyte antigen (HLA)-matched sibling donor available.</description>
        </group>
        <group group_id="P6">
          <title>High-dose Daunorubicin Then Allogeneic HCT or no Consolidation</title>
          <description>Induction: Patients receive high-dose daunorubicin IV over 10-15 minutes on days 1-3 and cytarabine IV continuously on days 1-7. Patients may receive a second course of induction therapy if complete remission (CR) is not achieved after the first course.
Consolidation/Transplant:
Patients without CR did not receive any consolidation treatment. Patients in CR with an unfavorable cytogenetic profile or an initial white blood cell count &gt; 100,000/μL were to proceed to allogeneic HCT if they had a suitable human leukocyte antigen (HLA)-matched sibling donor available.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Induction</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="79"/>
                <participants group_id="P2" count="90"/>
                <participants group_id="P3" count="63"/>
                <participants group_id="P4" count="75"/>
                <participants group_id="P5" count="188"/>
                <participants group_id="P6" count="162"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="79"/>
                <participants group_id="P2" count="90"/>
                <participants group_id="P3" count="63"/>
                <participants group_id="P4" count="75"/>
                <participants group_id="P5" count="186"/>
                <participants group_id="P6" count="160"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="79"/>
                <participants group_id="P2" count="90"/>
                <participants group_id="P3" count="63"/>
                <participants group_id="P4" count="75"/>
                <participants group_id="P5" count="128"/>
                <participants group_id="P6" count="108"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="60"/>
                <participants group_id="P6" count="54"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Disease progression</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="18"/>
                <participants group_id="P6" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="9"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Alternative therapy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other complicating disease</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Reasons not reported</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="22"/>
                <participants group_id="P6" count="25"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Conditioning/Transplant</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="79"/>
                <participants group_id="P2" count="90"/>
                <participants group_id="P3" count="63"/>
                <participants group_id="P4" count="75"/>
                <participants group_id="P5" count="21"/>
                <participants group_id="P6" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Randomized to Autologous HCT +/- GO</title>
              <participants_list>
                <participants group_id="P1" count="59">Additional 20 patients received Autologous HCT without randomization.</participants>
                <participants group_id="P2" count="73">Additional 17 patients received Autologous HCT without randomization.</participants>
                <participants group_id="P3" count="63"/>
                <participants group_id="P4" count="75"/>
                <participants group_id="P5" count="0">These 21 patients received Allogeneic HCT without randomization.</participants>
                <participants group_id="P6" count="0">These 24 patients received Allogeneic HCT without randomization.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="40"/>
                <participants group_id="P3" count="25"/>
                <participants group_id="P4" count="32"/>
                <participants group_id="P5" count="15"/>
                <participants group_id="P6" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="50"/>
                <participants group_id="P3" count="38"/>
                <participants group_id="P4" count="43"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Disease progression</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Alternative therapy</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other complicating disease</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Reasons not reported</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="31"/>
                <participants group_id="P3" count="18"/>
                <participants group_id="P4" count="15"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Standard Daunorubicin (Induction Therapy)</title>
          <description>Patients receive standard-dose daunorubicin IV over 10-15 minutes on days 1-3 and cytarabine IV continuously on days 1-7.
Patients may receive a second course of induction therapy if complete remission (CR) is not achieved after the first course.</description>
        </group>
        <group group_id="B2">
          <title>High Dose Daunorubicin (Induction Therapy)</title>
          <description>Patients receive high-dose daunorubicin IV over 10-15 minutes on days 1-3 and cytarabine as in arm I. Patients may receive a second course of induction therapy if CR is not achieved after the first course. The second course is administered as in arm I.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="330"/>
            <count group_id="B2" value="327"/>
            <count group_id="B3" value="657"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47" lower_limit="17" upper_limit="60"/>
                    <measurement group_id="B2" value="48" lower_limit="18" upper_limit="60"/>
                    <measurement group_id="B3" value="48" lower_limit="17" upper_limit="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="158"/>
                    <measurement group_id="B2" value="164"/>
                    <measurement group_id="B3" value="322"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="172"/>
                    <measurement group_id="B2" value="163"/>
                    <measurement group_id="B3" value="335"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival (Induction Phase)</title>
        <description>Overall survival is defined as the time from randomization in the induction phase to death.</description>
        <time_frame>Assessed during the first 4 months, then at least every three months for 2 years. then every six months until 5 years after study entry and every 12 months thereafter.</time_frame>
        <population>All randomized patients are included in the analysis (intention-to-treat).</population>
        <group_list>
          <group group_id="O1">
            <title>Standard Daunorubicin</title>
            <description>Induction: Patients receive standard-dose daunorubicin IV over 10-15 minutes on days 1-3 and cytarabine IV continuously on days 1-7. Patients may receive a second course of induction therapy if complete remission (CR) is not achieved after the first course. Patients with CR received consolidation treatment thereafter.</description>
          </group>
          <group group_id="O2">
            <title>High-dose Daunorubicin</title>
            <description>Induction: Patients receive high-dose daunorubicin IV over 10-15 minutes on days 1-3 and cytarabine IV continuously on days 1-7. Patients may receive a second course of induction therapy if complete remission (CR) is not achieved after the first course. Patients with CR received consolidation treatment thereafter.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (Induction Phase)</title>
          <description>Overall survival is defined as the time from randomization in the induction phase to death.</description>
          <population>All randomized patients are included in the analysis (intention-to-treat).</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="330"/>
                <count group_id="O2" value="327"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.7" lower_limit="12.7" upper_limit="19.0"/>
                    <measurement group_id="O2" value="23.7" lower_limit="19.0" upper_limit="31.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Disease-free Survival (Consolidation Phase)</title>
        <description>Disease-free survival is defined from the time of the confirmation of a complete remission via biopsy to the relapse of the disease.</description>
        <time_frame>Assessed during the first 4 months, then at least every three months for 2 years. then every six months until five years after study entry, and every 12 months thereafter.</time_frame>
        <population>Only 270 patients who were randomized in the consolidation phase are included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Autologous HCT</title>
            <description>Patients with CR in the induction phase were randomized to receive autologous HCT or GO/autologous HCT.</description>
          </group>
          <group group_id="O2">
            <title>Go/Autologous HCT</title>
            <description>Patients with CR in the induction phase were randomized to receive autologous HCT or GO/autologous HCT.</description>
          </group>
        </group_list>
        <measure>
          <title>Disease-free Survival (Consolidation Phase)</title>
          <description>Disease-free survival is defined from the time of the confirmation of a complete remission via biopsy to the relapse of the disease.</description>
          <population>Only 270 patients who were randomized in the consolidation phase are included in the analysis.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
                <count group_id="O2" value="138"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.0" lower_limit="11.4" upper_limit="23.9"/>
                    <measurement group_id="O2" value="13.6" lower_limit="10.7" upper_limit="18.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (Consolidation Phase)</title>
        <description>Overall survival is defined as the time from randomization in the consolidation phase to death.</description>
        <time_frame>Assessed during the first 4 months, then at least every three months for 2 years. then every six months until five years after study entry, and every 12 months thereafter.</time_frame>
        <population>Only 270 patients who were randomized in the consolidation phase are included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Autologous HCT</title>
            <description>Patients with CR in the induction phase were randomized to receive autologous HCT or GO/autologous HCT.</description>
          </group>
          <group group_id="O2">
            <title>Go/Autologous HCT</title>
            <description>Patients with CR in the induction phase were randomized to receive autologous HCT or GO/autologous HCT.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (Consolidation Phase)</title>
          <description>Overall survival is defined as the time from randomization in the consolidation phase to death.</description>
          <population>Only 270 patients who were randomized in the consolidation phase are included in the analysis.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
                <count group_id="O2" value="138"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.5" lower_limit="24.2" upper_limit="51.7"/>
                    <measurement group_id="O2" value="27.9" lower_limit="20.3" upper_limit="39.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Assessed weekly while on treatment and for 30 days after the end of treatment.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Standard Daunorubicin (Induction Therapy)</title>
          <description>Induction: Patients receive standard-dose daunorubicin IV over 10-15 minutes on days 1-3 and cytarabine IV continuously on days 1-7. Patients may receive a second course of induction therapy if complete remission (CR) is not achieved after the first course.
Conditioning/Transplant:
Patients receive conditioning comprising busulfan IV every 6 hours on days -7 to -4 and cyclophosphamide IV over 2 hours on days -3 and -2. Patients then undergo autologous peripheral blood stem cell (PBSC) transplantation on day 0. Patients receive sargramostim (GM-CSF) or filgrastim (G-CSF) IV or subcutaneously (SC) beginning on day 0 and continuing until blood counts recover.</description>
        </group>
        <group group_id="E2">
          <title>High Dose Daunorubicin (Induction Therapy)</title>
          <description>Induction: Patients receive high-dose daunorubicin IV over 10-15 minutes on days 1-3 and cytarabine as in arm I. Patients may receive a second course of induction therapy if CR is not achieved after the first course. The second course is administered as in arm I.
Conditioning/Transplant:
Patients receive gemtuzumab ozogamicin IV over 2 hours on day 1 and GM-CSF SC or IV beginning on day 10 and continuing until blood counts recover. Within 2-3 weeks after blood count recovery, patients receive conditioning and undergo autologous PBSC transplantation as in arm I.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (2.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="328" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="325" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="257" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="251" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Hemolysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="320" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="323" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="319" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="305" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="321" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="321" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Transfusion platelets</sub_title>
                <counts group_id="E1" subjects_affected="199" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="206" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Transfusion: PRBCS</sub_title>
                <counts group_id="E1" subjects_affected="197" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="191" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Hematologic-other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Weight gain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>DIC</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Bilirubin Increased</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>AST increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>ALT Increased</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="121" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="117" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>CNS hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Petechiae</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Sinus Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Supraventricular arrhythmias</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Ventricular arrthhmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Arrhythmia-other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Acute Vascular leak syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Cardiac ischemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Cardiac-Left Ventricular Function</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Cardiac Troponin I</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Pericardial Effusion/Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Cardiac-other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Typhlitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Proctitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Diarrhea w/o prior colostomy</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Diarrhea w/ prior colostomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>GI-other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Hematemesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Melena/GI Bleeding</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Rectal Bleeding</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Rectal or Perirectal Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>VOD</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Rigors/chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Constitutional symptoms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Pain-other</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Wound-infectious</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Infection w/ Gr3-4 neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="154" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="168" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Catheter-Related Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Infection w/ unknown ANC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Infection w/o neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Infection- Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Acidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Operative Injury of Vein/Artery</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Wound - non-infectious</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Hemorrhage with Grade 3 or 4 Platelets</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Hemorrhage without Grade 3 or 4 Platelets</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Hemorrhage Associated with Surgery</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>PTT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>SIADH</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Hypernatremia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Tumor Lysis Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bone Marrow Cellularity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Muscle Weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Myositis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Joint, Muscle, Bone-Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Bone, pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Dizziness/Lightheadedness</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Neuropathy-motor</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Neuropathy-sensory</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Speech Impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Ocular-Other</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Depressed Level of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Hallucinations</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Anxiety/Agitation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginal Bleeding</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Pleuritic Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>ARDS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Pneumonitis/pulmonary infiltrates</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Hand-Foot Reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Skin- Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flashes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Hemorrhage-Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (2.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="319" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="318" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="319" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="318" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="281" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="267" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="243" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="230" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="295" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="292" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="328"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Statistician</name_or_title>
      <organization>ECOG Statistical Office</organization>
      <phone>617-632-3012</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

